Georgia Governor Signs SB 220, Expanding Medical Cannabis Access for Patients

Georgia's medical cannabis program is entering a new era after Governor Brian Kemp signed Senate Bill 220, known as the 'Putting Georgia’s Patients First Act,' into law on May 12, 2026. The legislation introduces greater flexibility for patients and physicians, allowing them to tailor THC:CBD ratios to individual medical needs. For families like Shannon Cloud’s, whose daughter has struggled with seizures for two decades, this represents a long-awaited opportunity to find more effective treatment. Cloud emphasized, “It allows more flexibility for patients and doctors to access what’s really going to work for them, taking away the really tight restrictions.”

Despite vocal opposition from some members of the medical community, including a letter from psychiatrist Dr. Karen Drexler and Dr. Elizabeth McCord urging a veto, the bill advanced. The letter claimed that SB 220 would authorize "high-risk cannabis products, such as vapes and concentrates, that have no demonstrated safety or benefit for any medical condition," and warned of increased risks ranging from psychosis to heart attacks. However, these assertions have been challenged by recent peer-reviewed studies and medical guidelines. A 2024 clinical review published in Cannabis and Cannabinoid Research found vaporized cannabis to be an appropriate delivery method for patients needing fast-acting relief, with a low safety risk profile when managed properly

Critics of the opposition letter have pointed out that its claims lack citation from peer-reviewed literature and rely heavily on anecdotal evidence. For example, Dr. Drexler referenced a personal family tragedy to illustrate potential risks, but this was not backed by broader scientific consensus. In contrast, studies cited by proponents highlight the therapeutic potential of cannabinoids, including a meta-analysis of 15 randomized controlled trials showing significant pain reduction in patients. The American College of Physicians and the FDA have also recognized inhaled delivery methods for chronic pain management, further undercutting the letter's arguments

The debate over SB 220 has brought renewed attention to Georgia’s restrictive medical cannabis framework. According to the Georgia Medical Cannabis Commission's 2026 report, patients often found the program confusing and inaccessible, particularly when "low THC oil" was misunderstood as ineffective. With only 34,500 registered patients in a state of 11.3 million—far fewer than neighboring states like Mississippi and Louisiana—Georgia's adoption rate has lagged behind. Senate sponsor and physician Matt Brass acknowledged the shortcomings, stating, “For the patients that this program is designed to serve, it’s not always worked well enough.”

Governor Kemp’s signing statement recognized the unique needs of patients, noting, “I also recognize that for some patients, medical cannabis provides significant relief to symptoms that would otherwise go untreated or would be treated with even more harmful opioids.” The Georgia Access to Medical Cannabis Commission now has until January 1, 2027, to finalize regulations for new product formats. OG Lab notes that this legislative shift marks a pivotal moment for Georgia’s medical cannabis program, signaling a move toward a more patient-centered system and setting the stage for expanded access in the coming years